Breaking News Instant updates and real-time market news.

EIGR

Eiger BioPharmaceuticals

$10.50

-0.615 (-5.54%)

08:14
12/19/18
12/19
08:14
12/19/18
08:14

Eiger announces Breakthrough Therapy designation for lonafarnib

Eiger BioPharmaceuticals announced that the Food and Drug Administration has granted Breakthrough Therapy designation for lonafarnib for the treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies. FDA Breakthrough Therapy designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases. Progeria and progeroid laminopathies are ultra-rare, genetic conditions characterized by accelerated aging, with no approved treatment. Eiger is collaborating with The Progeria Research Foundation and plans to submit a new drug application to the FDA in 2019. Lonafarnib is a first-in-class prenylation inhibitor for the treatment for Progeria and progeroid laminopathies.This Breakthrough Therapy designation is supported by data from clinical studies of lonafarnib, demonstrating statistically significant improvements in survival in children with Progeria where the average survival age without treatment is 14.5 years.

EIGR Eiger BioPharmaceuticals
$10.50

-0.615 (-5.54%)

10/18/18
PIPR
10/18/18
NO CHANGE
Target $24
PIPR
Overweight
Eiger positive data opens HDV triple combo opportunity, says Piper Jaffray
Eiger BioPharmaceuticals last night announced positive end-of-treatment data from the Phase II study of InterferonLambda in hepatitis delta virus patients, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Importantly, Interferon-Lambda continued to show improved tolerability versus IFN-alfa, which should enable long-term dosing, the analyst contends. He believes the positive data opens up the opportunity for a hepatitis delta virus triple combo. Tenthoff reiterates an Overweight rating on shares of Eiger with a $24 price target.
10/17/18
PIPR
10/17/18
NO CHANGE
Target $24
PIPR
Overweight
Piper reiterates Overweight on Eiger after positive hypoglycemia data
Eiger BioPharmaceuticals last night reported positive top-line Phase II Prevent data on avexitide to treat post-bariatric hypoglycemia, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. The analyst points out that both primary and secondary endpoints achieved statistical significance showing clinically meaningful increases in glucose nadir and decreased insulin spike following induction of a hypoglycemic attack. He reiterates an Overweight rating on Eiger shares with a $24 price target. Tenthoff remains focused on Eiger's hepatitis delta virus franchise with full 48-week Phase II interferon lambda data at the annual American Association for the study of Liver Diseases meeting in November and the Phase III D-LIVR trial start of lonafarnib in Q4.
09/04/18
PIPR
09/04/18
NO CHANGE
Target $24
PIPR
Overweight
Eiger can file lonafarnib without additional studies, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says feedback from the FDA will enable Eiger BioPharmaceuticals to file an investigational new drug application for lonafarnib to treat orphan indication Hutchinson-Gilford Progeria syndrome as soon as 2019. Importantly, this accelerates anticipated timelines because Eiger is not required to conduct additional clinical studies for approval, Tenthoff tells investors in a research note. He beieves that if approved, Eiger "could gain a valuable Pediatric Priority Review Voucher shared with the Progeria Research Foundation." The analyst reiterates an Overweight rating on the shares with a $24 price target.
08/27/18
JEFF
08/27/18
NO CHANGE
Target $25
JEFF
Buy
Jefferies sees good entry point for Eiger BioPharmaceuticals ahead of update
Jefferies analyst Maury Raycroft believes current Eiger BioPharmaceuticals share levels offer a good entry point ahead of news from the Phase III D-LIVR endpoints in hepatitis delta virus based on FDA feedback. The analyst does not anticipate major surprises around the update and expect the outcome to be viewed positively. The announcement should give the stock a bump and add momentum to a second half of 2018 run-up that will include several key catalysts, Raycroft tells investors in a research note. He sees little downside risk in Eiger shares and keeps a Buy rating on the name with a $25 price target.

TODAY'S FREE FLY STORIES

TGT

Target

$111.05

-2.16 (-1.91%)

15:38
10/23/19
10/23
15:38
10/23/19
15:38
Hot Stocks
Target to add nearly $50M in payroll for holiday season »

Target announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$337.84

0.39 (0.12%)

15:37
10/23/19
10/23
15:37
10/23/19
15:37
Periodicals
DOT says FAA must restore confidence in aircraft certification, Reuters says »

The U.S. Transportation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

NSC

Norfolk Southern

$184.87

-3.98 (-2.11%)

, CSX

CSX

$72.19

-0.1 (-0.14%)

15:35
10/23/19
10/23
15:35
10/23/19
15:35
Downgrade
Norfolk Southern, CSX, Kansas City Southern, Union Pacific, Canadian National rating change  »

BofA downgrades Norfolk…

NSC

Norfolk Southern

$184.87

-3.98 (-2.11%)

CSX

CSX

$72.19

-0.1 (-0.14%)

KSU

Kansas City Southern

$146.06

1.02 (0.70%)

UNP

Union Pacific

$169.56

-1.26 (-0.74%)

CNI

Canadian National

$89.06

-0.8 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

  • 21

    Nov

  • 22

    Nov

LRCX

Lam Research

$231.75

-3.16 (-1.35%)

15:34
10/23/19
10/23
15:34
10/23/19
15:34
Options
Lam Research options imply 8.3% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Nov

  • 19

    Nov

  • 20

    Nov

15:31
10/23/19
10/23
15:31
10/23/19
15:31
Conference/Events
Morgan Stanley oil/gas E&P analysts to hold an analyst/industry conference call »

Analysts, along with…

POAI

Predictive Oncology

$0.41

-0.01 (-2.38%)

15:25
10/23/19
10/23
15:25
10/23/19
15:25
Conference/Events
Predictive Oncology to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

MU

Micron

$44.56

-0.12 (-0.27%)

15:23
10/23/19
10/23
15:23
10/23/19
15:23
Recommendations
Micron analyst commentary  »

Micron files annual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 06

    Nov

  • 20

    Nov

NSC

Norfolk Southern

$184.63

-4.22 (-2.23%)

15:22
10/23/19
10/23
15:22
10/23/19
15:22
Downgrade
Norfolk Southern rating change  »

Norfolk Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

EBAY

eBay

$39.00

0.03 (0.08%)

15:19
10/23/19
10/23
15:19
10/23/19
15:19
Options
EBay options imply 8.7% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 29

    Oct

GOGO

Gogo

$5.99

0.08 (1.35%)

15:18
10/23/19
10/23
15:18
10/23/19
15:18
Hot Stocks
Gogo AVANCE platform exceeds 175,000 business aviation flights »

Gogo Business Aviation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 20

    Nov

FSV

FirstService

$96.64

-8.71 (-8.27%)

15:18
10/23/19
10/23
15:18
10/23/19
15:18
Earnings
FirstService reports Q3 adjusted EPS 92c, consensus $1.03 »

Earlier, FirstService…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
10/23/19
10/23
15:17
10/23/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
10/23/19
10/23
15:16
10/23/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSV

FirstService

$96.64

-8.71 (-8.27%)

15:15
10/23/19
10/23
15:15
10/23/19
15:15
Earnings
Correction: FirstService reports Q3 adjusted EPS 92c, consensus $1.03 »

Earlier, FirstService…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FSV

FirstService

$96.64

-8.71 (-8.27%)

15:13
10/23/19
10/23
15:13
10/23/19
15:13
Recommendations
FirstService analyst commentary  »

FirstService estimates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

15:12
10/23/19
10/23
15:12
10/23/19
15:12
Conference/Events
Morgan Stanley financial services analysts hold analyst/industry conference call »

Financial Analysts Cyprys…

MSFT

Microsoft

$136.19

-0.2 (-0.15%)

15:07
10/23/19
10/23
15:07
10/23/19
15:07
On The Fly
Fly Intel: What to watch in Microsoft earnings report »

Microsoft (MSFT) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 14

    Nov

  • 21

    Nov

XOM

Exxon Mobil

$69.49

0.38 (0.55%)

15:06
10/23/19
10/23
15:06
10/23/19
15:06
Hot Stocks
Qilak LNG executes heads of agreement with ExxonMobil for natural gas »

Qilak LNG, a Lloyds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

XLNX

Xilinx

$93.83

-2.18 (-2.27%)

15:04
10/23/19
10/23
15:04
10/23/19
15:04
Options
Xilinx options imply 11.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 20

    Nov

FTNW

FTE Networks

$1.15

0.28 (32.18%)

14:52
10/23/19
10/23
14:52
10/23/19
14:52
Hot Stocks
Breaking Hot Stocks news story on FTE Networks »

FTE Networks Inc trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$254.68

-0.94 (-0.37%)

14:49
10/23/19
10/23
14:49
10/23/19
14:49
Options
Tesla options imply 11.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

KR

Kroger

$24.96

0.1 (0.40%)

14:45
10/23/19
10/23
14:45
10/23/19
14:45
Options
Kroger call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

14:45
10/23/19
10/23
14:45
10/23/19
14:45
General news
Treasury's $41 B 5-year auction was well supported »

Treasury's $41 B…

GSK

GlaxoSmithKline

$43.20

0.69 (1.62%)

, MYGN

Myriad Genetics

$32.14

-0.15 (-0.46%)

14:38
10/23/19
10/23
14:38
10/23/19
14:38
Hot Stocks
FDA approves niraparib for HRD-positive advanced ovarian cancer »

On October 23, the Food…

GSK

GlaxoSmithKline

$43.20

0.69 (1.62%)

MYGN

Myriad Genetics

$32.14

-0.15 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 30

    Oct

  • 06

    Nov

  • 13

    Nov

  • 07

    Dec

TSLA

Tesla

$253.92

-1.7 (-0.67%)

14:27
10/23/19
10/23
14:27
10/23/19
14:27
On The Fly
Fly Intel: What to watch in Tesla earnings report »

Tesla (TSLA) is scheduled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.